Novartis has gained exclusive rights to develop and market Debio 025 (alisporivir), a potential first-in-class antiviral agent currently in Phase IIb development for the treatment of hepatitis C.
Debio 025 is the first in a new class of drugs called cyclophilin inhibitors which could become part of the future standard of care for the disease.
Debio 025 has been in-licensed from Debiopharm Group under an agreement which gives Novartis exclusive worldwide development and marketing rights (excluding Japan).
The transaction is subject to customary regulatory approvals.
“Hepatitis C is sometimes referred to as a “silent epidemic” because the virus can lie dormant in the body for years or even decades before the symptoms become apparent,” said David Epstein, CEO of the Novartis Pharmaceuticals Division.
“Novartis is dedicated to developing medicines that will reduce the impact of this disease on patients, and we believe that Debio 025 could prove an important step forward by significantly enhancing the efficacy of existing therapy that forms the standard of care for hepatitis C.”
To find out more, please click on the link below: